The US Food and Drug Administration (FDA) has announced a shift in how it oversees the development of cell and gene therapies, aiming to lower regulatory barriers that have complicated the path from laboratory to clinic.
FDA commissioner Dr Martin Makary described the adjustments as 'common-sense reforms' that recognise the field's scientific advances.
Please visit Pharmaphorum for more information.